Interleukin 18 as a marker of chronic nephropathy in children after anticancer treatment

Disease Markers

Volumn 35, Issue 6, 2013, Pages 811-818

  Zubowska, Małgorzata ^a   Wyka, Krystyna ^a   Fendler, Wojciech ^a   Młynarski, Wojciech ^a   Zalewska Szewczyk, Beata ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; IFOSFAMIDE; INTERLEUKIN 18; KIDNEY INJURY MOLECULE 1;

ABDOMINAL RADIOTHERAPY; ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CHRONIC KIDNEY DISEASE; COMPARATIVE STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY TUBULE DISORDER; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; NEPHROTOXICITY; PRIORITY JOURNAL;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; CISPLATIN; FEMALE; HUMANS; IFOSFAMIDE; INTERLEUKIN-18; KIDNEY; KIDNEY NEOPLASMS; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RENAL INSUFFICIENCY, CHRONIC; ROC CURVE; WILMS TUMOR;

EID: 84896931541     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2013/369784     Document Type: Article

References (37)

1. Geenen M. M., Cardous-Ubbink M. C., Kremer L. C. M., van den Bos C., van der Pal H. J. H., Heinen R. C., Jaspers M. W. M., Koning C. C. E., Oldenburger F., Langeveld N. E., Hart A. A. M., Bakker P. J. M., Caron H. N., Van Leeuwen F. E., Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. Journal of the American Medical Association 2007 297 24 2705 2715 2-s2.0-34347218640 10.1001/jama.297.24.2705
2. Mulrooney D. A., Dover D. C., Li S., Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia: a report from the Childhood Cancer Survivor Study. Cancer 2008 112 9 2071 2079 10.1002/cncr.23405
3. Kurt B. A., Nolan V. G., Ness K. K., Neglia J. P., Tersak J. M., Hudson M. M., Armstrong G. T., Hutchinson R. J., Leisenring W. M., Oeffinger K. C., Robison L. L., Arora M., Hospitalization rates among survivors of childhood cancer in the childhood cancer survivor study cohort. Pediatric Blood & Cancer 2012 59 1 126 132 10.1002/pbc.24017
4. Lee B. S., Lee J. H., Kang H. G., Hahn H., Lee J. H., Shin H. Y., Ha I. S., Cheong H. I., Ahn H. S., Choi Y., Ifosfamide nephrotoxicity in pediatric cancer patients. Pediatric Nephrology 2001 16 10 796 799 2-s2.0-0034820648 10.1007/s004670100658
5. Rossi R., Pleyer J., Schäfers P., Kuhn N., Kleta R., Deufel T., Jürgens H., Developement of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients. Medical and Pediatric Oncology 1999 32 3 177 182
6. Skinner R., Sharkey I. M., Pearson A. D. J., Craft A. W., Ifosfamide, mesna, and nephrotoxicity in children. Journal of Clinical Oncology 1993 11 1 173 190 2-s2.0-0027462532
7. Skinner R., Cotterill S. J., Stevens M. C. G., Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. British Journal of Cancer 2000 82 10 1636 1645 2-s2.0-0034014698
8. Skinner R., Pearson A. D. J., English M. W., Price L., Wyllie R. A., Coulthard M. G., Craft A. W., Risk factors for ifosfamide nephrotoxicity in children. The Lancet 1996 348 9027 578 580 2-s2.0-0030608224 10.1016/S0140-6736(96)03480-0
9. Skinner R., Pearson A. D. J., Price L., Cunningham K., Craft A. W., Hypophosphataemic rickets after ifosfamide treatment in children. British Medical Journal 1989 298 6687 1560 1561 2-s2.0-0024390566
10. Knijnenburg S. L., Jaspers M. W., van der Pal H. J., Schouten-van Meeteren A. Y., Bouts A. H., Lieverst J. A., Bökenkamp A., Koning C. C., Oldenburger F., Wilde J. C., van Leeuwen F. E., Caron H. N., Kremer L. C., Renal dysfunction and elevated blood pressure in long-term childhood cancer survivors. Clinical Journal of the American Society of Nephrology 2012 7 9 1416 1427 10.2215/CJN.09620911
11. Skinner R., Parry A., Price L., Cole M., Craft A. W., Pearson A. D. J., Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose. Pediatric Blood and Cancer 2010 54 7 983 989 2-s2.0-77951763538 10.1002/pbc.22364
12. Oberlin O., Fawaz O., Rey A., Niaudet P., Ridola V., Orbach D., Bergeron C., Defachelles A. S., Gentet J. C., Schmitt C., Rubie H., Munzer M., Plantaz D., Deville A., Minard V., Corradini N., Leverger G., de Vathaire F., Long-term evaluation of ifosfamide-related nephrotoxicity in children. Journal of Clinical Oncology 2009 27 32 5350 5355 2-s2.0-73949098182 10.1200/JCO.2008.17.5257
13. Skinner R., Parry A., Price L., Cole M., Craft A. W., Pearson A. D. J., Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors. European Journal of Cancer 2009 45 18 3213 3219 2-s2.0-70450161199 10.1016/j.ejca.2009.06.032
14. Washburn K. K., Zappitelli M., Arikan A. A., Loftis L., Yalavarthy R., Parikh C. R., Edelstein C. L., Goldstein S. L., Urinary interleukin-18 is an acute kidney injury biomarker in critically ill children. Nephrology Dialysis Transplantation 2008 23 2 566 572 2-s2.0-43049122996 10.1093/ndt/gfm638
15. Rosner M. H., Urinary biomarkers for the detection of renal injury. Advances in Clinical Chemistry 2009 49 73 97 2-s2.0-73349109833
16. Ho E., Fard A., Maisel A., Evolving use of biomarkers for kidney injury in acute care settings. Current Opinion in Critical Care 2010 16 5 399 407 2-s2.0-78449292830 10.1097/MCC.0b013e32833e10bc
17. Liang X. L., Liu S. X., Chen Y. H., Yan L. J., Li H., Xuan H. J., Liang Y. Z., Shi W., Combination of urinary kidney injury molecule-1 and interleukin-18 as early biomarker for the diagnosis and progressive assessment of acute kidney injury following cardiopulmonary bypass surgery: a prospective nested casecontrol study. Biomarkers 2010 15 4 332 339 2-s2.0-77952528239 10.3109/13547501003706558
18. Koyner J. L., Vaidya V. S., Bennet M. R., Ma Q., Worcester E., Akhter S. A., Raman J., Jeevanandam V., O'Connor M. F., Devarajan P., Bonventre J. V., Murray P. T., Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury. Clinical Journal of the American Society of Nephrology 2010 5 12 2154 2165 10.2215/CJN.00740110
19. Parikh C. R., Lu J. C., Coca S. G., Devarajan P., Tubular proteinuria in acute kidney injury: a critical evaluation of current status and future promise. Annals of Clinical Biochemistry 2010 47 4 301 312 2-s2.0-77954418915 10.1258/acb.2010.010076
20. Widemann B. C., Balis F. M., Kim A., Boron M., Jayaprakash N., Shalabi A., O'Brien M., Eby M., Cole D. E., Murphy R. F., Fox E., Ivy P., Adamson P. C., Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome. Journal of Clinical Oncology 2010 28 25 3979 3986 2-s2.0-77957566458 10.1200/JCO.2009.25.4540
21. Darmon M., Guichard I., Vincent F., Schlemmer B., Azoulay L., Prognostic significance of acute renal injury in acute tumor lysis syndrome. Leukemia and Lymphoma 2010 51 2 221 227 2-s2.0-76349092225 10.3109/10428190903456959
22. Janeway K. A., Grier H. E., Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. The Lancet Oncology 2010 11 7 670 678 2-s2.0-77954031237 10.1016/S1470-2045(10)70062-0
23. Ashraf M. S., Brady J., Breatnach F., Deasy P. F., O'Meara A., Ifosfamide nephrotoxicity in paediatric cancer patients. European Journal of Pediatrics 1994 153 2 90 94 2-s2.0-0027952814 10.1007/s004310050092
24. Zielińska E., Zubowska M., Misiura K., Role of GSTM1, GSTP1, and GSTT1 gene polymorphism in ifosfamide metabolism affecting neurotoxicity and nephrotoxicity in children. Journal of Pediatric Hematology/Oncology 2005 27 11 582 589 2-s2.0-28144457187 10.1097/01.mph.0000187429.52616.8a
25. Stöhr W., Paulides M., Bielack S., Jürgens H., Treuner J., Rossi R., Langer T., Beck J. D., Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the late effects surveillance system. Pediatric Blood and Cancer 2007 48 4 447 452 2-s2.0-33847361458 10.1002/pbc.20858
26. Skinner R., Chronic ifosfamide nephrotoxicity in children. Medical and Pediatric Oncology 2003 41 3 190 197 2-s2.0-0042343605 10.1002/mpo.10336
27. Marina N. M., Poquette C. A., Cain A. M., Jones D., Pratt C. B., Meyer W. H., Comparative renal tubular toxicity of chemotherapy regimens including ifosfamide in patients with newly diagnosed sarcomas. Journal of Pediatric Hematology/Oncology 2000 22 2 112 118 2-s2.0-0034457381 10.1097/00043426- 200003000-00007
28. Arjmandi-Rafsanjani K., Hooman N., Vosoug P., Renal function in late survivors of Iranian children with cancer: single centre experience. Indian Journal of Cancer 2008 45 4 154 157 2-s2.0-58149269430 10.4103/0019-509X.44663
29. Camano S., Lazaro A., Moreno-Gordaliza E., Torres A. M., de Lucas C., Humanes B., Lazaro J. A., Gomez-Gomez M. M., Bosca L., Tejedor A., Cilastatin attenuates cisplatin-induced proximal tubular cell damage. Journal of Pharmacology and Experimental Therapeutics 2010 334 2 419 429 2-s2.0-77954929399 10.1124/jpet.110.165779
30. Moore E., Bellomo R., Nichol A., Biomarkers of acute kidney injury in anesthesia, intensive care and major surgery: from the bench to clinical research to clinical practice. Minerva Anestesiologica 2010 76 6 425 440 2-s2.0-77954981818
31. Che M., Xie B., Xue S., Dai H., Qian J., Ni Z., Axelsson J., Yan Y., Clinical usefulness of novel biomarkers for the detection of acute kidney injury following elective cardiac surgery. Nephron Clinical Practice 2010 115 1 c66 c72 2-s2.0-76749088441 10.1159/000286352
32. Oberbauer R., Biomarkers-A potential route for improved diagnosis and management of ongoing renal damage. Transplantation Proceedings 2008 40 10 S44 S47 2-s2.0-57649095374 10.1016/j.transproceed.2008.10.005
33. Devarajan P., The future of pediatric acute kidney injury management-biomarkers. Seminars in Nephrology 2008 28 5 493 498 2-s2.0-51249094102 10.1016/j.semnephrol.2008.05.010
34. Trof R. J., Di Maggio F., Leemreis J., Groeneveld A. B. J., Biomarkers of acute renal injury and renal failure. Shock 2006 26 3 245 253 2-s2.0-33747360138 10.1097/01.shk.0000225415.5969694.ce
35. Siew E. D., Ikizler T. A., Gebretsadik T., Shintani A., Wickersham N., Bossert F., Peterson J. F., Parikh C. R., May A. K., Ware L. B., Elevated urinary IL-18 levels at the time of ICU admission predict adverse clinical outcomes. Clinical Journal of the American Society of Nephrology 2010 5 8 1497 1505 2-s2.0-77955724098 10.2215/CJN.09061209
36. Wu H., Craft M. L., Wang P., Wyburn K. R., Chen G., Ma J., Hambly B., Chadban S. J., IL-18 contributes to renal damage after ischemia-reperfusion. Journal of the American Society of Nephrology 2008 19 12 2331 2341 2-s2.0-57149102957 10.1681/ASN.2008020170
37. Edelstein C. L., Biomarkers of acute kidney injury. Advances in Chronic Kidney Disease 2008 15 3 222 234 2-s2.0-44949204503 10.1053/j.ackd.2008.04.003